Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026Business Wire • 05/30/26
SMMT Q1 Loss Narrower Than Expected, Stock Down on Ivonescimab SetbackZacks Investment Research • 05/04/26
Summit Therapeutics Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their LossesGlobeNewsWire • 05/04/26
Summit Therapeutics Reports Financial Results and Operational Progress for the First Quarter Ended March 31, 2026Business Wire • 04/30/26
Multiple Ivonescimab Data Sets from Phase III Studies in Advanced NSCLC Patient Populations to be Featured at ELCC 2026Business Wire • 03/27/26
Summit Therapeutics Inc. (SMMT) Presents at The Citizens Life Sciences Conference 2026 TranscriptSeeking Alpha • 03/11/26
Summit Therapeutics Inc. (SMMT) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/02/26
SMMT Incurs Wider-Than-Expected Q4 Loss, Pipeline Progress in FocusZacks Investment Research • 02/24/26
Summit Therapeutics Reports Financial Results and Operational Progress for the Fourth Quarter and Year Ended December 31, 2025Business Wire • 02/23/26
Summit Therapeutics to Host Fourth Quarter and Full Year 2025 Financial Results & Operational Progress Call on February 23, 2026Business Wire • 02/17/26
Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire • 01/30/26
Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI TherapyBusiness Wire • 01/29/26
Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference TranscriptSeeking Alpha • 01/12/26
Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC)Business Wire • 01/12/26